Evidence map›Paper›PMID 39609108›Full record

ArticleCancer science2025

GPNMB is a novel binding partner of FGFR1 that affects tumorigenic potential through AKT phosphorylation in TNBC.

Manar A Elhinnawi, Yukari Okita, Katsunobu Shigematsu, Mohammed Abdelaziz, Rie Shiratani, Kunio Kawanishi, Kowit Hengphasatporn, Thuy Linh Dang Cao, Yasuteru Shigeta, Mitsuyasu Kato

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Vasorelaxant and Hypotensive Mechanisms ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manar A ElhinnawiDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0002-0061-9060
Yukari OkitaDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0002-7279-4634
Katsunobu ShigematsuDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Mohammed AbdelazizDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Rie ShirataniDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Kunio KawanishiDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Kowit HengphasatpornCenter for Computational Sciences, University of Tsukuba, Ibaraki, Japan.
Thuy Linh Dang CaoDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Yasuteru ShigetaCenter for Computational Sciences, University of Tsukuba, Ibaraki, Japan.
Mitsuyasu KatoDepartment of Experimental Pathology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-9905-2473

Funding

Japan Society for the Promotion of Science JP20K20597Japan Society for the Promotion of Science JP22K07184Japan Society for the Promotion of Science JP24K02257Takeda Science Foundation
6 · The paper itself

Abstract

Breast cancer is a heterogeneous disease and is one of the most prevalent cancers in women. Triple-negative breast cancer (TNBC) is a relatively aggressive subtype of breast cancer, which is difficult to treat. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type I transmembrane protein that is overexpressed in various types of cancers, including breast cancer, especially TNBC. In this study, bioinformatic analyses revealed enhanced fibroblast growth factor receptor 1 (FGFR1) signaling in patients with invasive breast cancer, and the GPNMB

Indexed as

Membrane GlycoproteinsProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 1Triple Negative Breast NeoplasmsAnimalsCarcinogenesisCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleHumansMiceMolecular Docking SimulationPhosphorylationProtein BindingFGFR1 protein, humanGPNMB protein, humanMembrane GlycoproteinsProto-Oncogene Proteins c-aktReceptor, Fibroblast Growth Factor, Type 1cell migrationepithelial–mesenchymal transitionfibroblast growth factor receptor 1glycoprotein nonmetastatic melanoma protein Btriple‐negative breast cancer

Identifiers

PMID39609108
PMCPMC11786315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.